請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27907
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 金傳春(Chwan-Chuen King) | |
dc.contributor.author | Pui-I Ho | en |
dc.contributor.author | 何佩怡 | zh_TW |
dc.date.accessioned | 2021-06-12T18:27:15Z | - |
dc.date.available | 2016-10-03 | |
dc.date.copyright | 2011-10-03 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-08 | |
dc.identifier.citation | Baguelin M, Hoschler K, et al. Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation. PLoS One 2011;6(2): e17074.
Balter, S., L. S. Gupta, et al. Pandemic (H1N1) 2009 surveillance for severe illness and response, New York, New York, USA, April-July 2009. 2010;Emerg Infect Dis 16(8): 1259-1264. Bandaranayake D, Huang QS, et al. Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic. PLoS One 2010;5(10): e13211. Bhattarai A, Villanueva J, et al. Viral shedding duration of pandemic influenza A H1N1 virus during an elementary school outbreak--Pennsylvania, May-June 2009. Clin Infect Dis 2011;52 Suppl 1: S102-108. Cauchemez S, Donnelly CA, et al. Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States. N Engl J Med 2009;361(27): 2619-2627. Cauchemez S, Ferguson NM, et al. Closure of schools during an influenza pandemic. Lancet Infect Dis 2009;9(8): 473-481. Cauchemez S, Valleron AJ, et al. Estimating the impact of school closure on influenza transmission from Sentinel data. Nature 2008;452(7188): 750-754. Center of Disease Control and Prevention. Swine influenza A (H1N1) infection in two children – Southern California, March – April 2009. MMWR Morb Mortal Wkly Rep 2009;58:400-402. Chang, SC, Chang CM, et al. Preexisting antibodies against pandemic 2009 influenza A (H1N1) virus in Taiwan. 2010;Clin Infect Dis 51(12): 1465-1467. Chao DL, Halloran ME, et al. School opening dates predict pandemic influenza A(H1N1) outbreaks in the United States. J Infect Dis 2010;202(6): 877-880. Chao DY, Cheng KF, et al. Serological evidence of subclinical transmission of the 2009 pandemic H1N1 influenza virus outside of Mexico. PLoS One 2011;6(1): e14555. Cheong HJ, Song JY, et al. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. Vaccine 2011;29(3): 523-527. Chi CY, Liu CC, et al. Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population. Clin Vaccine Immunol 2010;17(12): 1958-1962. Choe YJ, Cho H, et al. Active Surveillance of Adverse Events Following Immunization against Pandemic Influenza A (H1N1) in Korea. Jpn J Infect Dis 2011;64(4): 297-303. Chu YC. Evaluation of human influenza mass-vaccination among grade 1-2 elementary schoolchildren during 2007-2008 in Taiwan. National Taiwan University 2009 Cowling BJ, Chan KH, et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010;362(23): 2175-2184. Dawood FS, Jain S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360(25): 2605-2615. Effler PV, Carcione D, et al. Household responses to pandemic (H1N1) 2009-related school closures, Perth, Western Australia. Emerg Infect Dis 2010;16(2): 205-211. France AM, Jackson M et al. Household transmission of 2009 influenza A (H1N1) virus after a school-based outbreak in New York City, April-May 2009. J Infect Dis 2010;201(7): 984-992. Garcia-Sicilia J, Gillard P, et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 2011;29(26): 4353-4361. Garten RJ, Davis CT, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325(5937): 197-201. Gift TL, Palekar RS, et al. Household effects of school closure during pandemic (H1N1) 2009, Pennsylvania, USA. Emerg Infect Dis 2010;16(8): 1315-1317. Haber P, Sejvar J, et al. Vaccines and Guillain-Barre syndrome. 2009;Drug Saf 32(4): 309-323. Hancock K, Veguilla V, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361(20): 1945-1952. Hancock K. Serologic Detection of Human Influenza Virus Infections by Hemaggluination-Inhibition Assay Using Turkey RBCs. US-CDC 2009;LP-003, R-1 Hardelid P, Fleming DM, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Euro Surveill 2011;16(2). Heymann AD, Hoch I, et al. School closure may be effective in reducing transmission of respiratory viruses in the community. Epidemiol Infect 2009;137(10):1369-76. Hsueh PR, Lee PI, et al. Pandemic (H1N1) 2009 vaccination and class suspensions after outbreaks, Taipei City, Taiwan. Emerg Infect Dis 2010;16(8): 1309-1311. Huang DT, Shao PL, et al. Serologic status for pandemic (H1N1) 2009 virus, Taiwan. 2011;Emerg Infect Dis 17(1): 76-78. Iwatsuki-Horimoto K, Horimoto T, et al. Seroprevalence of pandemic 2009 (H1N1) influenza A virus among schoolchildren and their parents in Tokyo, Japan. Clin Vaccine Immunol 2011;18(5): 860-866. Jackson C, Mangtani P, et al. School closures and student contact patterns. Emerg Infect Dis 2011;17(2): 245-247. Jhung MA, Swerdlow D, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis 2011;52 Suppl 1: S13-26. Jick H and Hagberg KW. Effectiveness of influenza vaccination in the United kingdom, 1996-2007. Pharmacotherapy 2010;30(12): 1199-1206. Kao CL, Tsai CH, et al. Emerging Hemagglutinin Mutations in of Pandemic Influenza A (H1N1) Viruses in Taiwan, 2009-2010. Options for the Control of Influenza VII, Hong Kong, 2010. Kar-Purkayastha I, Ingram C, et al. The importance of school and social activities in the transmission of influenza A(H1N1)v: England, April - June 2009. Euro Surveill 2009; 14(33). Kawaguchi R, Miyazono M, et al. Influenza (H1N1) 2009 outbreak and school closure, Osaka Prefecture, Japan. Emerg Infect Dis 2009;15(10): 1685. Lee CK, Lee HK, et al. Comparison of pandemic (H1N1) 2009 and seasonal influenza viral loads, Singapore. Emerg Infect Dis 2011;17(2): 287-291. Liang XF, Li L, et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N Engl J Med 2011;364(7): 638-647. Looker C, Carville K, et al. Influenza A (H1N1) in Victoria, Australia: a community case series and analysis of household transmission. PLoS One 2010;5(10): e13702. Lu CY, Shao PL, et al. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine 2010;28(36): 5864-5870. Miller E, Hoschler K, et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010;375(9720): 1100-1108. Miller JC, Danon L, et al. Student behavior during a school closure caused by pandemic influenza A/H1N1. PLoS One 2010;5(5): e10425. Nolan T, McVernon J, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010;303(1): 37-46. Ortqvist A, Berggren I, et al. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis 2011;52(10): 1203-1211. Papenburg J, Baz M, et al. Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory-confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis 2010;51(9): 1033-1041. Scheifele DW, Ward BJ, et al. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. Pediatr Infect Dis J 2011;30(5): 402-407. Shore S, Shinkai S, et al. Immune responses to training: how critical is training volume? J Sports Med Phys Fitness 1999;39(1): 1-11. Sikora C, Fan S, et al. Transmission of pandemic influenza A (H1N1) 2009 within households: Edmonton, Canada. J Clin Virol 2010;49(2): 90-93. Skowronski DM, Janjua NZ, et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011;342: c7297. Song JY, Cheong HJ, et al. Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. Vaccine 2011;29(7): 1395-1398. Sugimoto JD, Borse NN, et al. The effect of age on transmission of 2009 pandemic influenza A (H1N1) in a camp and associated households. Epidemiology 2011;22(2): 180-187. Tian, L. L., W. X. Shi, et al. Serologic survey of pandemic influenza A (H1N1 2009) in Beijing, China. Prev Med 2011;52(1): 71-74. Tsai TF, Pedotti P, et al. Regional and age-specific patterns of pandemic H1N1 influenza virus seroprevalence inferred from vaccine clinical trials, August-October 2009. Euro Surveill 2010;15(30). US-CDC. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. 2009;MMWR Morb Mortal Wkly Rep 58(48): 1351-1356. Valenciano M, Kissling E, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med 2011;8(1): e1000388. Veguilla V, Hancock K, et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 2011;49(6): 2210-2215. Wright PF. The use of inactivated influenza vaccine in children. Semin Pediatr Infect Dis 2006;17(4): 200-205. Wu JT, Cowling BJ, et al. School closure and mitigation of pandemic (H1N1) 2009, Hong Kong. Emerg Infect Dis 2010;16(3): 538-541. Wu JT, Ma ES, et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis 2010;51(10): 1184-1191. Wu J, Xu F, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010;363(25): 2416-2423. Zimmer SM, Crevar CJ, et al. Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS One 2010;5(7): e11601. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27907 | - |
dc.description.abstract | 新型流感H1N1(pdmH1N1)於2009年在全球肆虐,臺灣政府為了延緩其蔓延,在9月1日開始推行新的停課政策 ─「325停課標準」;並於11月16日對全國中、小學童推廣免費疫苗接種。本研究目的有四:(1)探討在停課高峰後和施打疫苗前,學童新型流感病毒之感染盛行率;(2)找出感染新型流感H1N1病毒的危險因子;(3)比較學童在接種疫苗前後其血清抗體效價之變化;及(4)評估預防接種成效之相關因子。
自2009年11月至2010年3月間,在臺北和高雄各擇選兩所國小二年級至六年級972和1,028位學童,進行血清流行病學世代研究。在獲得家長簽署同意書後,始採集臺北學童三時間點[接種疫苗前 (T1)、接種疫苗後一個月(T2)和接種疫苗後四個月(T3)]與高雄學童兩時間點[T1和T3] 的血清;續以血球凝集抑制試驗(Hemagglutination Inhibition Assay, HI) 測量參與學童對新型流感H1N1疫苗株 [A/California/07/2009(H1N1)] 的抗體反應。單變項分析是以t檢定 (Student t test) 和卡方檢定 (Chi-square test) 比較兩組 (如有、無接種疫苗,有、無停課等) 之間的差異;再以複邏輯斯迴歸 (multiple logistic regression) 、整合廣義估計方程式 [廣估式] (General Estimating Equation) 調整同班學童間的相關性以分析感染新型流感之危險因子及使用複線性迴歸(multiple linear regression)分析接種疫苗後抗體衰退之因子。 結果顯示接種疫苗前臺北學童的2009年新型流感病毒H1N1的感染率 (HI血清效價≥1:10) 遠較高雄學童(49.02% vs 29.74%, p<0.0001)。而有停課學童的感染率也高於沒有停課的學童 (59.60% v.s. 47.45%, p=0.0241)。以廣估式控制性別、年齡、身體質量指數(body mass index)、前驅病史(co-morbidity)後,發現參加課後活動和每週運動多於三小時是臺北學童感染新型流感的危險因子,其調整後勝算比(adjusted odds ratio)分別為2.47 [95% 信賴區間(Confidence Interval, CI):1.02-6.00, p=0.0458) 和2.86 (95% CI:1.19-6.86, p=0.0189);而高雄學童的危險因子為托管於安親班,其調整後勝算比為2.02 (95% CI:1.33-3.07, p=0.001)。粗估臺北與高雄學童的新型流感H1N1病毒的顯性:不顯性感染比分別是1:1-2 和 1:7-12。 在評估疫苗方面,安全性上發現有15.13%的臺北與高雄學童在接種新型流感H1N1疫苗後7天內有不良反應[其中2.35%接種者有發燒] ,但無嚴重副作用。兩地學童於T3的2009年新型流感病毒H1N1血清保護率(seroprotection rate, HI血清效價≥1:40)各為89.00% 和83.33% (p=0.0368),群體免疫力已達80%以上。有趣的是臺北國小四至六(高)年級學童有接種新型流感H1N1疫苗者的pdmH1N1血清保護率較無接種疫苗者為高 (89.60% v.s. 48.65%, p<0.0001);但在國小二、三(低)年級差異較小(88.67% v.s. 86.67%, p= 0.0545)。而高雄高低年級學童有接種疫苗者的血清保護率均顯著較無接種疫苗者為高 (低年級:78.18% v.s. 41.67%, p=0.0110;高年級:84.30% v.s. 63.64%, p=0.0010)。新型流感H1N1疫苗效益在臺北學童基於兩種自然感染定義 (在T2至T3間有至少1倍以上的上升或至少4倍上升)介於41.3% 與 79%之間。而針對接種一劑和兩劑疫苗的臺北低年級學童,兩者pdmH1N1血清保護力差別不大 [從T2至T3,一劑:由83.12%至83.72%,兩劑: 75.73%至91.80%]。在沒有接種疫苗的臺北學童中,低年級的學童在T1至T2[11.36% v.s.2.83% (p=0.0342)]與T1至T3[15.91% v.s.4.72% (p=0.0214)]的自然感染率均高於高年級。其中67.07% 接種疫苗學童的血清效價在T2至T3間下降。進一步分析學童於接種疫苗後(只包括接種一劑疫苗) 抗體衰退 (antibody waning) 的相關因子,發現在T2至T3期間,控制性別後,每週運動多於三小時 (p=0.0184) 為主要因子。重要的是家長在讓子女接種疫苗時,主要考量疫苗安全性、疫苗效果和是否有副作用。 本研究提供科學實證基礎與方向,以因應未來新型流感再侵入臺灣的公共衛生重要決策,包括:(1)以班級為單位停課確實可延緩流行,但停課效果受限於學童的行為和習慣,家長和老師應提醒學童避免於停課期間外出活動;(2)針對學童接種流感疫苗確實可阻斷流行,學童本次全面接種臺灣自製的新型流感H1N1疫苗後,血清保護率達90%,顯示其能有效地增加抗體保護和群體免疫力;及(3)若疫苗劑量不足時,及早施打一劑仍有阻斷傳播之效。未來將比較城鄉與不同年齡之流行差異,並每年追蹤流感流行的變化,貫徹瞭解不同型別流感病毒之流行特性和社區傳播模式,以建立監測系統即早偵測下一波新型流感的入侵;並經國際合作,以標準作業流程與方法評估不同策略對流行的影響,共同敦促建立跨國流感聯合防治網絡。 | zh_TW |
dc.description.abstract | The pandemic influenza A/H1N1 (pdmH1N1) was occurred in 2009. To mitigate the contagion, the Taiwanese government implemented a new “325 class suspensions” strategy on September 1 and initiated a nationwide schoolchildren influenza pdmH1N1 vaccination campaign on November 16. The specific aims of this study were: (1) to investigate the seroprevalence of the 2009 pdmH1N1 virus infection in elementary schoolchildren after the peaks of class suspension and before the vaccination of the first dose, (2) to investigate the risk factors associated with the 2009 pdmH1N1 infection, (3) to compare the serotiters of anti-pdmH1N1 antibodies among schoolchildren before and after the vaccination, and (4) to evaluate vaccine effectiveness and its related factors.
A pdmH1N1 seroepidemiological cohort study was conducted among schoolchildren from November 2009 to March 2010. Written informed consents were obtained from parents before blood drawing from 972 and 1028 2-6 graders each of the two elementary schools in Taipei and Kaohsiung, respectively. Serum levels of anti-pdmH1N1 antibody were measured for samples collected at three time points [pre-vaccination (T1), 1-month post-vaccination (T2) and 4-month post vaccination (T3)] for Taipei and two time points [T1 and T3] for Kaohsiung using the A/California/07/2009 (H1N1) vaccine strain as test virus for the hemagglutination inhibition (HI) assay. Univariate analysis was conducted to compare the differences between subgroups (vaccinated v.s. unvaccinated, with v.s. without class suspension) using Student t test and chi-square test. Multiple logistic regression analysis was integrated with General Estimating Equation (GEE) in adjusting correlation of students within the same class was applied to query the risk factors for acquiring the 2009 pdmH1N1 infection; multiple linear regression was conducted to analyze factors associated with the waning of antibody. The overall seroprevalence rate (HI serotiters≥1:10) of schoolchildren before vaccination was significantly higher in Taipei than that in Kaohsiung (49.02% v.s. 29.74%, p<0.0001), especially among classmates who had experienced class suspension (59.60% v.s. 47.45%, p=0.0241). After controlling for gender, grade body mass index and comorbidity were risk factors for acquiring pdmH1N1 infection among schoolchildren in Taipei were attending after-school activities [adjusted odds ratios of 2.47 [95% Confidence Interval (CI): 1.02-6.00, p=0.0458] and having exercise ≥ 3 hours/week [adjusted odds ratio of 2.86 (95% CI: 1.19-6.86, p=0.0189)]. Similarly, the factor associated with infection for Kaohsiung schoolchildren was attending day care center, with adjusted odds ratio of 2.02 (95% CI: 1.33-3.07, p=0.001). The acquisition of pdmH1N1 was ascribed to those unvaccinated yet seropositive children, for whom the symptomatic: asymptomatic infection ratios were estimated to be 1:1-2 and 1:7-12 for children in Taipei and Kaohsiung, respectively. In evaluating the pdmH1N1 vaccine, a total of 15.13% vaccinees reported having at least one post-vaccination adverse events within 7 days (fever≥38℃: 2.35%) but no one was considered serious. The overall seroprotection rates (HI serotiters≥1:40) at T3 were 89.00% and 83.33% for vaccines in Taipei and Kaohsiung (p=0.0368), respectively. For the upper (4-6) graders in Taipei, the post epidemic seroprotection rate of vaccinees was significantly higher than unvaccinated schoolchildren (89.6% v.s. 48.65%, p<0.0001) suggesting a low infection rate among the upper graders. For the lower (2-3) graders, seroprotection rate among the unvaccinated children was as high as that of the vaccinees (88.67% v.s. 86.67%, p=0.0545). The seroprotection rates of Kaohsiung vaccinated schoolchildren were significantly higher than unvaccinated ones in both grades (lower: 78.18% v.s. 41.67%, p=0.110; upper: 84.3% v.s. 63.64%, p=0.0010). The vaccine effectiveness ranged 41.3%-79%, according to the two criteria of natural infection (T3/T2 serotiter rise: ≥1-fold or ≥4-folds). In comparing the lower grade students vaccinated with one or two doses, the seroprotection rates between these two groups were alike (T2 to T3, 1 dose: 83.12% to 83.72%; two doses: 75.73% to 91.50%. The natural infection rates among unvaccinated lower graders were higher than upper graders (T1 to T2: 11.36% v.s. 2.83%, p=0.0342; T1 to T3: 15.91% v.s. 4.72%, p=0.0214). The antibody of two-thirds (67.7%) of vaccinated children showed waning titers from T2 to T3. Those who exerise≥3 hrs/wk were more likely to show antibody waning (p=0.0184, after controlling gender) in 1-dose vaccinees from T2 to T3. Questionnaire showed the main concerns of parents about vaccination against the 2009 pdmH1N1 were vaccine safety and effectiveness. This study provided evidence-based information for the public health policies in preparedness of future pandemics, including: (1)Class suspension can mitigate the epidemic, yet its effect was limited by the behaviors and habits of schoolchildren, implying that parents and teachers should remind them to avoid gathering; (2) mass-vaccination on schoolchildren did block the epidemic while seroprotection rates reached to 90%, demonstrating that Taiwan’s domestically made 2009 pdmH1N1 vaccine was effective in increasing herd immunity; and (3) prompt vaccination with one dose can block the contagion if vaccine is in shortage. Future studies will investigate the epidemiological differences in metropolitans and remote areas, in different age groups for monitoring changes in each influenza seasons; understanding the characteristics of different influenza subtypes and transmission in community, and establishing an efficient surveillance system for early detection of next pandemic. With international collaboration the impact of different public health strategies using standard operation procedures and methods can be carefully evaluated for co-establishing united prevention and control network for influenza. | en |
dc.description.provenance | Made available in DSpace on 2021-06-12T18:27:15Z (GMT). No. of bitstreams: 1 ntu-100-R98842002-1.pdf: 3162791 bytes, checksum: 8ffdc5a515b159cdbafc0d8404b8a2bc (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 論文口試委員審定書 i
Acknowlegements 誌謝 ii Chinese Abstract中文摘要 iii Abstract v Contents viii Figure Contents xii Table Contents xiv Appendix Contents xvii Chapter 1 Introduction 1 Chapter 2 Literature Review 3 2.1 The 2009 Pandemic Influenza A (H1N1) Virus 3 2.1.1 Global Perspectives 3 2.1.2 Taiwan’s Status 7 2.2 Public Health Intervention 8 2.2.1 School Closure 8 2.2.2 Vaccination 10 Chapter 3 Objectives, Specific Aims and Hypotheses 15 3.1 Objective 15 3.2 Specific Aims 15 3.3 Hypotheses 16 Chapter 4 Materials and Methods 17 4.1 Study Design and Study Population 17 4.1.1 Schoolchildren Cohort in Taipei 17 4.1.2 Schoolchildren Cohort in Kaohsiung 18 4.2 Data Collection 18 4.3 Laboratory Methods 19 4.3.1 Collection and Storage of Serum Samples 19 4.3.2 Receptor Destroying Enzyme (RDE) Treatment 20 4.3.3 Source of the 2009 Pandemic Influenza A (H1N1) Virus Strain 20 4.3.4 Hemagglutination (HA) Assay 20 4.3.5 Hemagglutination Inhibition (HI) Assay 21 4.4 Term Definitions 21 4.4.1 Anti-H1N1 Antibody Definitions 21 4.4.2 Influenza-like Illness (ILI) 22 4.4.3 Adverse Events after Vaccination 22 4.5 Data Analyses and Statistical Tests 23 4.5.1 Outcome Measures 23 4.5.2 Data Analyses 24 4.5.3 Statistical Methods 24 Chapter 5 Results 26 5.1 Characteristics of Study Cohort 26 5.1.1 Participation Rates and Follow-up Rates 26 5.1.2 Analysis between Participants and Non-participants 27 5.1.3 Demographic Analysis of Participants 28 5.2 The 2009 pdmH1N1 infection and Risk Factors at Pre-vaccination 30 5.2.1 Total Infection Rate of the 2009 pdmH1N1 before Vaccination 30 5.2.2 Risk Factors Associated with the 2009 pdmH1N1 Infection 32 5.2.3 The Asymptomatic Ratios of 2009 pdmH1N1 34 5.3 Vaccination Program 35 5.3.1 Adverse Events after the Vaccination 35 5.3.2 The Immunogenicity of the 2009 pdmH1N1 Vaccine 36 5.3.3 The Seroincidence Rates and Natural Infection Rates among Unvaccinated Students throughout the Study Period 40 5.3.4 Patterns of Serotiter Changes after Receiving the 2009 pdmH1N1 Vaccine and the Factors Associated with Antibody Waning 41 5.3.5 Vaccine Effectiveness 42 5.4 Attitudes and Knowledge from Parents of Kaohsiung Elementary Schoolchildren on Intervention Policies 43 Chapter 6 Discussion 45 6.1 Geographic Variations of Anti-pdmH1N1 Antibody Reponses between Taipei and Kaohsiung 46 6.1.1 Different Levels of Transmission before Implementing the School-wide Vaccination Program 46 6.1.2 Asymptomatic Ratios of the 2009 pdmH1N1 Infections 48 6.1.3 Seroincidence Rates and Natural Infection Rates 49 6.2 Evaluation of the 2009 pdmH1N1 Vaccine 50 6.2.1 Immunogenicity of the 2009 pdmH1N1 Vaccine 50 6.2.2 1-dose versus 2-dose vaccine 50 6.2.3 Vaccine Effectiveness 51 6.2.4 Antibody Waning 52 6.3 Impacts of Public Health Interventions 52 6.3.1 Class Suspension 52 6.3.2 Vaccination 54 6.4 Limitations 55 6.5 Recommendations and Future Perspectives 56 References 58 Figures 64 Tables 75 Appendix 99 | |
dc.language.iso | en | |
dc.title | 以臺灣國小學童的2009年新型流感H1N1抗體評估停課與疫苗政策 | zh_TW |
dc.title | Antibody Responses of the 2009 Pandemic Influenza A (H1N1) among Elementary Schoolchildren in Taiwan: Evaluation of Class Suspension and Vaccination | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 何美鄉(Mei-Shang Ho),李秉穎(Ping-Ing Lee),李文宗(Wen-Chung Lee),顏慕庸(Muh-Yong Yen),李敏西(Min-Shi Lee),林先和(Hsien-Ho Lin) | |
dc.subject.keyword | 2009新型流行性感冒,傳播模式,流感疫苗預防接種政策,停課,血清流行病學,危險因子,臺灣,公共衛生防疫策略, | zh_TW |
dc.subject.keyword | 2009 Pandemic Influenza A (H1N1),Transmission,Vaccination,School Closure,Seroepidemiology,Risk Factors,Taiwan,Public Health Policies, | en |
dc.relation.page | 126 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-08 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 3.09 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。